分析师将 KalVista Pharmaceuticals 评级上调至“强烈买入”和“买入”评级，尽管第二季度未及预期。 Analysts upgrade KalVista Pharmaceuticals to "strong-buy" and "buy" ratings, despite Q2 miss.

Cantor Fitzgerald将KalVista药品升级为“强购”评级, HC Wainwright重申以20美元的价格目标“买”。 Cantor Fitzgerald upgraded KalVista Pharmaceuticals to a "strong-buy" rating and HC Wainwright reaffirmed a "buy" with a $20 price target. 临床阶段制药公司侧重于HAE和DME的小分子蛋白抑制剂,内幕出售股票,机构投资者增加其持有量。 The clinical-stage pharmaceutical company, with a focus on small molecule protease inhibitors for HAE and DME, saw insiders sell shares and institutional investors increase their holdings. 尽管第二季度收益不及预期，但 KalVista 得到了分析师和投资者的支持。 Despite a Q2 earnings miss, KalVista has received support from analysts and investors.